Company news

Penumbra, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Penumbra, Inc. Reports Third Quarter 2026 Financial Results

October 29, 2026

Penumbra's CAVT Technology Receives FDA Clearance for the Treatment of Deep Vein Thrombosis (DVT)

October 20, 2026

Penumbra, Inc. Reports Second Quarter 2026 Financial Results

July 30, 2026

THUNDER Study Demonstrates Penumbra's THUNDERBOLT is Safe and Effective for Stroke Care

July 22, 2026

First Patient Enrolled in Penumbra's FORWARD Study Evaluating Mechanical Thrombectomy and Computer Assisted Vacuum Thrombectomy for Distal Acute Ischemic Stroke

July 7, 2026

Penumbra Expands CAVT for Stroke to Europe with CE Mark for THUNDERBOLT

June 15, 2026

Penumbra's THUNDERBOLT Receives FDA Clearance - Bringing Computer Assisted Vacuum Thrombectomy Technology to Stroke

June 11, 2026

Penumbra, Inc. Reports First Quarter 2026 Financial Results

May 6, 2026

New STORM-PE Data Show Computer Assisted Vacuum Thrombectomy with Anticoagulation Resulted in Significantly Better Functional Outcomes at 90 Days Compared to Anticoagulation Alone for Pulmonary Embolism Patients

April 13, 2026

Penumbra, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results

February 25, 2026

Boston Scientific announces results for fourth quarter and full year 2025

February 4, 2026

Penumbra, Inc. Provides Preliminary Update on Fourth Quarter and Full Year 2025 Financial Results

January 15, 2026

Penumbra, Inc. to Present at the 44th Annual J.P. Morgan Healthcare Conference

December 29, 2025

Penumbra, Inc. to Present at the Piper Sandler 37th Annual Healthcare Conference

November 19, 2025

Penumbra, Inc. Reports Third Quarter 2025 Financial Results

November 5, 2025

Latest Data from Landmark STORM-PE Randomized Controlled Trial Demonstrate that CAVT with Anticoagulation Significantly Improves Functional Outcomes for Patients with Pulmonary Embolism

November 3, 2025

Landmark STORM-PE Randomized Controlled Trial Finds Computer Assisted Vacuum Thrombectomy (CAVT) with Anticoagulation Superior to Traditional Anticoagulation Treatment for Pulmonary Embolism

October 27, 2025

Penumbra, Inc. Schedules Investor Event at TCT Conference on October 26, 2025; Earnings Release and Conference Call for Third Quarter 2025 Scheduled for November 5, 2025

October 8, 2025

Penumbra, Inc. Names Shruthi Narayan as Company President

August 27, 2025

Penumbra, Inc. to Present at Upcoming Investor Conferences

August 20, 2025

Penumbra, Inc. to Present at the Canaccord Genuity 45th Annual Growth Conference

July 30, 2025

Penumbra, Inc. Reports Second Quarter 2025 Financial Results

July 29, 2025

Penumbra, Inc. Schedules Second Quarter 2025 Earnings Release and Conference Call for July 29, 2025

July 1, 2025

Penumbra, Inc. Announces Completion of Enrollment for Landmark STORM-PE Randomized Controlled Trial

June 16, 2025

Penumbra Introduces the Ruby® XL System - the Longest, Largest, and Softest Coil on the Market for Vascular Embolization

June 5, 2025

Penumbra, Inc. to Present at the BofA Securities 2025 Health Care Conference

April 29, 2025

Penumbra, Inc. Reports First Quarter 2025 Financial Results

April 23, 2025

Penumbra, Inc. Schedules First Quarter 2025 Earnings Release and Conference Call for April 23, 2025

April 3, 2025

Seven New Data Sets Demonstrate Penumbra's Computer Assisted Vacuum Thrombectomy (CAVT) Technology Is Safe, Fast and Effective, Improves Patient Outcomes, and Delivers Healthcare Resource Benefits

April 2, 2025

Penumbra, Inc. Announces Don Kassing will Retire from Board of Directors

February 21, 2025

Penumbra, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results

February 18, 2025

Calls

The 5 newest of 23 calls. Every call is listed under its year.

Decks